StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $14.14 | $14.00 | -0.99% | 0.1M |
| 05-14 | $13.92 | $13.83 | -0.65% | 0.1M |
| 05-15 | $13.51 | $13.16 | -2.59% | 0.2M |
| 05-18 | $13.25 | $12.56 | -5.21% | 0.4M |
| 05-19 | $12.40 | $12.08 | -2.58% | 0.3M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Each factor shows KZIA's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
KZIA files a foreign annual report (20-F) — limited XBRL coverage.
Foreign issuer. Files an annual 20-F with the SEC instead of 10-K/10-Q, and the XBRL tags often differ. We pull what we can; if a row reads 'Not available' the issuer didn't tag that line item.
Public market data, filings, and news are still available on this ticker via the other tabs.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.